Total neoadjuvant therapy in rectal cancer: the evidence and expectations

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001090" target="_blank" >RIV/00064190:_____/23:10001090 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10470658 RIV/00216208:11110/23:10470658
Result on the web
<a href="https://doi.org/10.1016/j.critrevonc.2023.104196" target="_blank" >https://doi.org/10.1016/j.critrevonc.2023.104196</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.critrevonc.2023.104196" target="_blank" >10.1016/j.critrevonc.2023.104196</a>

Result language
angličtina
Original language name
Total neoadjuvant therapy in rectal cancer: the evidence and expectations
Original language description
Current management of locally advanced rectal cancer achieves high cure rates, distant metastatic spread being the main cause of patients' death. Total neoadjuvant therapy (TNT) employs (chemo)radiotherapy and combined chemotherapy prior to surgery to improve the treatment outcomes. TNT has been shown to reduce significantly distant metastases, increase disease-free survival by 5 - 10% in 3 years, and finally also overall survival (ALMOST EQUAL TO 5% in 7 years). It proved to double the rate of pathologic complete responses, making it an attractive strategy for non-operative management to avoid permanent colostomy in patients with distal tumors. In addition, it endorses adherence to the therapy due to better tolerance and, potentially, shortens its overall duration. A number of questions related to TNT remain currently unresolved including the indications, preferred radiotherapy and chemotherapy regimens, their sequence, timing of surgery, and role of adjuvant therapy. A stratified approach may be the optimal way to go. (C) 2023 The Authors
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)